BofA Securities Upgrades Akero Therapeutics (AKRO) to Buy

BofA Securities analyst Jason Zemansky upgraded Akero Therapeutics (NASDAQ: AKRO) from Neutral to Buy with a price target of $63.00 (from $35.00).

For an analyst ratings summary and ratings history on Akero Therapeutics click here. For more ratings news on Akero Therapeutics click here.

Shares of Akero Therapeutics closed at $54.00 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• BTIG Upgrades Tidewater Inc (TDW) to Buy, 'Increasing Activity Set To Push Dayrates Higher in Key Basins'
• TETRA Technologies Inc. (TTI) PT Lowered to $10 at Northland